ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 028,28
1,13%
Dow Jones
41 488,19
1,65%
DAX
22 986,82
2,01%
Brent Oil
70,285
0,00%
Bitcoin
84 003,58
-0,41%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NLS Pharmaceutics Ltd (NLSP)

  7. NLS Pharmaceutics Ltd (NLSP) Actualités

NLSP

NLS Pharmaceutics (NLSP)

NLS Pharmaceutics Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NLSP
DateHeureSourceTitreSymboleSociété
10/03/202512h00PR Newswire (US)NLS Pharmaceutics CEO Issues Letter to ShareholdersNASDAQ:NLSPNLS Pharmaceutics Ltd
27/02/202513h00PR Newswire (US)NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist PlatformNASDAQ:NLSPNLS Pharmaceutics Ltd
25/02/202515h05PR Newswire (US)Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes TreatmentNASDAQ:NLSPNLS Pharmaceutics Ltd
10/02/202513h30PR Newswire (US)NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 TherapiesNASDAQ:NLSPNLS Pharmaceutics Ltd
31/01/202513h30PR Newswire (US)Kadimastem Shareholders Approved the Merger with NLS PharmaceuticsNASDAQ:NLSPNLS Pharmaceutics Ltd
30/01/202513h30PR Newswire (US)NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual MeetingNASDAQ:NLSPNLS Pharmaceutics Ltd
28/01/202513h30PR Newswire (US)NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl DependenceNASDAQ:NLSPNLS Pharmaceutics Ltd
16/01/202515h32PR Newswire (US)Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLSNASDAQ:NLSPNLS Pharmaceutics Ltd
08/01/202513h42PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share PriNASDAQ:NLSPNLS Pharmaceutics Ltd
30/12/202413h30PR Newswire (US)NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed MergerNASDAQ:NLSPNLS Pharmaceutics Ltd
04/12/202419h15PR Newswire (US)NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the MarketNASDAQ:NLSPNLS Pharmaceutics Ltd
27/08/202422h01Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:NLSPNLS Pharmaceutics Ltd
26/08/202422h40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NLSPNLS Pharmaceutics Ltd
15/07/202415h16Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NLSPNLS Pharmaceutics Ltd
14/06/202314h38Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NLSPNLS Pharmaceutics Ltd
05/05/202322h37Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
01/05/202322h31Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:NLSPNLS Pharmaceutics Ltd
24/02/202313h56Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/02/202312h10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
23/01/202312h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/01/202322h03Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:NLSPNLS Pharmaceutics Ltd
21/12/202222h03Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:NLSPNLS Pharmaceutics Ltd
16/12/202222h58Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
10/06/202222h44Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:NLSPNLS Pharmaceutics Ltd
02/06/202218h15TipRanksBrookline Capital Markets Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
04/05/202220h25TipRanksBrookline Capital Markets Sticks to Their Buy Rating for NLS Pharmaceutics (NLSP)NASDAQ:NLSPNLS Pharmaceutics Ltd
14/04/202222h49Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:NLSPNLS Pharmaceutics Ltd
13/04/202214h18Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:NLSPNLS Pharmaceutics Ltd
17/03/202215h36TipRanksMaxim Group Thinks NLS Pharmaceutics’ Stock is Going to RecoverNASDAQ:NLSPNLS Pharmaceutics Ltd
01/11/202113h31Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1/a)NASDAQ:NLSPNLS Pharmaceutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NLSP

Dernières Valeurs Consultées

BIT
S27864
Societe Generale Effekten
BIT
I09209
Intesa Sanpaolo
LSE
LSEG
London Stock Exchange
BIT
P17RW5
BNP Paribas Issuance
BIT
UB7XME
Unicredit Bank
BIT
NSCIT1382786
Cooperatieve Rabobank UA
COIN
ARETH
Arweave
USOTC
ORGS
Orgenesis (QX)
DBI
4N8C
DAXsubsector All Auto Pa...
NASDAQ
PALI
Palisade Bio
NASDAQI
FN55GI
First North Basic Materi...
BIT
P1DDB7
BNP Paribas Issuance
FX
MYRUSD
MYR vs US Dollar
BIT
S32122
Societe Generale Effekten
BIT
P1PV40
BNP Paribas Issuance
COIN
NIIUSD
Nahmii
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces